-
GTA 6 Release Date Confirmed for November 19; Troubleshooting Pre-load and Launch Errors
-
Peaceful Repeat Vote in Douglas Ward 3 Amid Heightened Security
-
‘They want silence’: how the film NAZA is shaking Israel
-
Belgian Ambassador Marks King’s Day in Athens Amidst Strong Bilateral Trade Ties
-
Dún Laoghaire-Rathdown €335m Budget Faces Mixed Reaction Over Housing and Cost of Living
-
Rediff.com IPO Risks: Gmail Dominance and New Business Ventures
-
BING X: 22,624.66 SNC have disappeared at BingX – how safe are tokens on BingX? Will BingX’s MiCAR licence be suspended?
-
Dubai Police Expand Luxury Patrol Fleet with 525-hp Defender
-
Iran Strikes US Sites in Kuwait Following US Airstrikes on Qeshm Island
-
Newsmax Expands Over-the-Air Reach with HC2 Broadcasting Distribution Agreement for Newsmax2
-
Dolphin Congratulates Shore Fire Media and Its Clients on 20 GRAMMY(R) Nominations, Including 10 Best Album Nods Across Diverse Genres
-
Impala and Philanthropy Southwest Launch Southwest Hub, Mapping Philanthropy Across Eight States
-
HTB Activ(TM) Trial Demonstrates Significant Improvement in Cognitive Abilities
-
Nixxy Announces 1-for-20 Reverse Stock Split
-
IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1 for Agitation in Alzheimer's Dementia
-
The IRS Watchdog Just Published Its FY 2027 Challenges List - Clear Start Tax Explains Why Agency Strain Rarely Slows Down Collection Notices
-
Who Does the Best Deep Plane Facelift in Oklahoma?
-
LHH ICEO Research Led by Harvard Business School Professor Maps Four Paths for Work Beyond the C-Suite
-
cbdMD Applauds Introduction of the Bipartisan Hemp Guardrails Act, Calling It a Win for Consumer Safety, American Jobs and Tax Revenue
-
Bell Rose Capital (OTCID:BELR) Makes Major Move Into Streaming Entertainment With Spark TV Partnership And New Billy Carson Series "The Missing Chapter"
-
Investments & Wealth Institute Expands Advanced Education Offerings for 2027, Announces Next Experience Conference in Nashville
-
Dermata Announces U.S. Trademark Registration for TOME(R)
-
Olenox October Bitcoin Production Climbs to Three-Month High as Uptime and Hashrate Advance
-
5E Advanced Materials Highlights Commercial Momentum in First Month as an Operating Borates Producer
-
Trout CPA Expands Partner Leadership with Michael Carr and Dan Lerew
-
Tocvan Defines Priority Gold Target Areas at Gran Pilar From Project-Wide Soil Sampling and Geologic Mapping; 225 Soils at or Above 100 ppb Gold
-
Jumia Reports Third Quarter 2026 Results
-
Fulcrum Metals PLC Announces Uranium Readings up to 0.42% U(3)O(8) at Charlot-Neely
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 18
-
SmartBuyerAI Gives Car Buyers an Itemized Check of Dealer Offers as FTC Steps Up Price Transparency Enforcement
-
What to Do When Two Households Become One
-
DataMeds AI Subsidiary Helomics, Inc. Announces Cancer Target Discovery and Anticancer Peptides Drug Development Partnership With DiaGen AI, Inc.
-
AbTherx Licenses Atlas(TM) Platform to Athenova Therapeutics for Next-Generation Targeted Alpha Radiopharmaceutical Discovery
-
1933 Industries Completes LED Lighting Retrofit at Its 68,000 Sq. Ft. Cannabis Cultivation Facility in Las Vegas, Nevada - Ranks #3 in Cannabis Flower Sales
-
Ameriwest Advances Its Copper Focused Strategy Through Proposed Sale of Railroad Valley to Pure Energy Minerals
-
DSS Announces Completion of Impact Biomedical Business Combination with Zoar Limited
-
Who Does the Best Deep Plane Facelift in Sarasota?
-
American Resources Corporation Provides Strategic Business and Financial Reporting Update
-
Silver Storm to Attend the 121 Mining Investment Conference in London, UK
-
Rockhaven Announces Successful Completion of 2026 Klaza Bulk Sample Program
-
NuRAN Wireless Raises First Two Towers in Benin as 4G Rollout Beats Expectations in Cameroon and Ivory Coast
-
ESGold Expands Montauban Gold-Silver Property to Approximately 26,787 Hectares Through Strategic Claim Staking
-
Wedgewood Weddings Acquires Swan Lake Overlook, Where Alpacas, Deer, and Mountain Views Join the Guest List
-
TrizCom PR Wins Fourth PRSA Dallas Best of Show Award; Founder Jo Trizila Receives Norm Teich Award
-
Paris Hilton Guides Loti as Chief Advocacy Officer to Put Digital Identity Protection in Everyone's Hands
-
UCLA's Scooter Jackson named Week 11 Lott IMPACT Trophy Player of the Week
-
Oleria Extends Identity Governance to AI Agents, Tracing Every Agent Through the People and Credentials It Acts For
-
Bill Shelow, LIBRA Insurance Partners President and CEO, Receives NAILBA’s 2026 Douglas Mooers Award for Excellence
-
Digital Infrastructure World 2027 Announces First 85 Speakers as Registrants Represent 80GW of AI Buying Capacity
-
Wyyerd Fiber Brings Arizona's Fastest Internet to the City of Phoenix
Obesity drugs give Danish economy a major boost
Massive demand for diabetes and weight loss drugs made by Danish pharmaceutical group Novo Nordisk have turned it into Europe's most valuable company, giving Denmark's economy a major makeover.
"If it wasn't for Novo Nordisk there wouldn't have been any growth" in the first six months of the year, Danske Bank chief economist Las Olsen told AFP.
The company's earnings have ballooned thanks to two in-demand prescription medications: type 2 diabetes drug Ozempic -- made famous by US celebrities for its weight loss side effects -- and obesity drug Wegovy.
In the first half of 2023, Denmark's economy grew by 1.7 percent year-on-year, official data showed.
Excluding the pharma industry, it shrank by 0.3 percent.
"We've never seen anything like it, it's changing the picture of the economy," said Statistics Denmark analyst Jonas Petersen.
Industrial production in Denmark "is up 40 percent compared to pre-pandemic levels," noted Palle Sorensen, chief economist at Nykredit bank.
By comparison, "in the eurozone in general and in the US it's pretty much at the same level as before the pandemic," he said.
That "also means that the recovery from the pandemic has been stronger."
The Novo Nordisk effect is seen in the state's coffers -- the company is the country's biggest taxpayer -- as well as in Denmark's trade balance and employment figures.
- Ramping up production -
Already the world's biggest insulin maker, Novo Nordisk saw sales of its obesity treatments soar by 157 percent in the first half of the year.
The World Health Organization says more than a billion people suffer from obesity. More than 530 million have diabetes, according to the International Diabetes Federation.
On the back of its strong first-half sales, the company raised its full-year forecast and now expects 2023 sales to grow by 30 percent from last year's 177 billion kroner ($25.5 billion).
Novo Nordisk's market capitalisation has soared to 2.98 trillion kroner, dethroning French luxury goods maker LVMH to become Europe's biggest listed company on September 1.
Denmark's gross domestic product reached 2.83 trillion kroner in 2022 and is expected to grow by 1.2 percent this year.
The injectable drug Ozempic has grown hugely popular for its weight loss properties, though it is officially only prescribed for diabetes.
Wegovy, an anti-obesity treatment launched in the United States two years ago and now also available in Denmark, Germany, Norway and the UK, saw its sales soar by 344 percent in the first half of the year.
"We are serving more patients than ever before," chief executive Lars Fruergaard Jorgensen said when the company released its earnings report in August
The drugmaker is currently unable to meet the surge in demand and plans to build a new plant in Denmark to ramp up production.
- Stabilising effect -
Experts warned that the company's success should not overshadow difficulties in the Danish economy.
"Other industrial firms in Denmark have a similar path to those of the rest of Europe and the US," Palle Sorensen said.
The Confederation of Danish Industry says the country's economy is "heavily influenced by a few select companies".
In 2022, another Danish titan, global shipping leader Maersk, posted record profits on the back of soaring freight prices.
"Denmark's total industrial production has increased by 11 percent over the past year, but if we disregard the pharmaceutical industry, industrial production has fallen by 11 percent," the Confederation's chief economist Allan Sorensen said.
Analysts say Novo Nordisk's rapid growth poses few risks and will likely have a stabilising effect on the economy.
"When the Danish economy becomes more dependent on pharmaceuticals, we are actually less exposed to the global business cycle because demand is quite steady over the business cycle," Palle Sorensen said.
"So that stabilises the Danish economy."
The company's success has also led to large foreign currency flows.
"There is a very large currency inflow coming from Novo Nordisk selling all this medicine outside of the country, but there's also a currency off-flow from the surpluses that Novo Nordisk is making, because the vast majority of the shareholders are in other countries," Olsen said.
To prevent the euro-pegged Danish krone from soaring too high, the central bank has kept its key interest rate below that of the European Central Bank, currently at 3.35 percent compared to the ECB's 3.75 percent.
D.Johnson--AT